Opportunity Information: Apply for PA 14 083
Apply for PA 14 083
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Neuroimmune Signaling and Function in Substance Use Disorders (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Feb 4, 2014 and posted on Feb 4, 2014.
- Applicants must submit their applications by May 7, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Small businesses For profit organizations other than small businesses City or township governments Public housing authorities/Indian housing authorities Public and State controlled institutions of higher education Independent school districts Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) State governments Others (see text field entitled Additional Information on Eligibility for clarification) County governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Neuroimmune Signaling and Function in Substance Use Disorders (R21) funding opportunity (PA-14-083) was a National Institutes of Health (NIH) discretionary grant program designed to stimulate exploratory, early-stage research on how immune-like signaling in the brain influences substance use disorders (SUDs). The central scientific focus was neuroimmune signaling within the central nervous system (CNS), meaning the molecular and cellular pathways through which immune mediators and immune-responsive brain cells (and related signaling molecules) shape neural activity. The FOA encouraged applicants to look across multiple levels of analysis, including molecular mechanisms, cellular responses, neural circuits, and measurable behaviors, with the aim of clarifying how these neuroimmune processes relate to drug use trajectories and outcomes.
A key theme of the opportunity was connecting neuroimmune activity to the full course of addiction-related phenomena. Applications were encouraged to address how neuroimmune signaling may contribute to the initiation of drug use, the escalation from initial exposure to heavier or more compulsive use, and the maintenance of SUDs over time. Just as importantly, the FOA emphasized neurological consequences associated with SUDs, such as brain changes that may persist and influence cognition, mood, stress responsivity, or vulnerability to future substance use. The announcement also highlighted abstinence, withdrawal, and relapse as critical stages of interest, signaling that NIH was looking for studies that examine neuroimmune dynamics during cessation of drug use, the biological and behavioral processes that unfold during withdrawal, and the mechanisms that may set the stage for renewed drug seeking after a period of abstinence.
The broader goal was to advance an understudied area by determining whether neuroimmune responses act mainly as risk factors that worsen addiction vulnerability and outcomes, as protective responses that buffer the brain and behavior against harm, or as context-dependent mechanisms that can do either depending on timing, substance type, dose, stress exposure, genetics, developmental stage, or comorbid conditions. In practical terms, this framing supported research that could help identify new biomarkers of risk and progression, uncover novel therapeutic targets, and refine prevention or intervention strategies by accounting for immune-brain interactions rather than viewing SUDs purely through traditional neurotransmitter or behavioral frameworks.
From an administrative standpoint, this was an R21 mechanism, which generally supports exploratory and developmental projects that can test new ideas, generate preliminary data, or open up promising new research directions that are not yet ready for larger-scale funding. The award ceiling listed for this opportunity was $200,000. There was no cost sharing or matching requirement. The program was associated with CFDA number 93.279 (Drug Abuse and Addiction Research Programs), aligning it with NIH efforts to support research on drug abuse and addiction.
Eligibility was broad and included many types of organizations, reflecting an intent to draw in diverse research teams and institutional settings. Eligible applicants included public and private institutions of higher education, nonprofits (both with and without 501(c)(3) status), small businesses, for-profit organizations (including those other than small businesses), and multiple levels of government such as state, county, city or township governments, special district governments, and independent school districts. The FOA also explicitly welcomed applications from tribal governments and tribal organizations, public housing authorities/Indian housing authorities, and a range of mission-driven or capacity-building institutions such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian-serving institutions, and Asian American and Native American Pacific Islander-serving institutions (AANAPISIs). Faith-based and community-based organizations and eligible federal agencies were also included. Notably, non-U.S. entities (foreign organizations and foreign institutions) were eligible to apply, non-U.S. components of U.S. organizations were eligible, and foreign components were allowed under NIH policy, supporting international or multinational collaborations where scientifically justified.
The opportunity was posted on February 4, 2014, and the final listed closing date was May 7, 2017, with an archive date of June 7, 2017, indicating the FOA is no longer active but remains accessible for reference. The full announcement was available through the NIH Grants Guide at http://grants.nih.gov/grants/guide/pa-files/PA-14-083.html, and NIH Office of Extramural Research (OER) webmaster contact information was provided for access or linking issues (FBOWebmaster@OD.NIH.GOV).
FAQs: Neuroimmune Signaling and Function in Substance Use Disorders (R21) - PA-14-083
What is the PA-14-083 funding opportunity?
PA-14-083, titled Neuroimmune Signaling and Function in Substance Use Disorders (R21), was a National Institutes of Health (NIH) discretionary grant program intended to stimulate exploratory, early-stage research on how immune-like signaling in the brain influences substance use disorders (SUDs).
Which NIH grant mechanism did this opportunity use?
This funding opportunity used the NIH R21 mechanism, which generally supports exploratory and developmental projects aimed at testing new ideas, generating preliminary data, or opening new research directions that are not yet ready for larger-scale funding.
What scientific area did the FOA focus on?
The central scientific focus was neuroimmune signaling within the central nervous system (CNS). This includes molecular and cellular pathways through which immune mediators, immune-responsive brain cells, and related signaling molecules influence neural activity in ways that may affect SUD risk, progression, and outcomes.
What kinds of research questions were encouraged?
The FOA encouraged research examining how neuroimmune signaling relates to substance use disorders across multiple levels of analysis, such as molecular mechanisms, cellular responses, neural circuits, and measurable behaviors, with the goal of clarifying how neuroimmune processes connect to drug use trajectories and outcomes.
Which stages of substance use and addiction were emphasized?
Applications were encouraged to address neuroimmune signaling across the full course of addiction-related phenomena, including initiation of drug use, escalation from initial exposure to heavier or more compulsive use, and maintenance of SUDs over time.
Did the FOA include abstinence, withdrawal, and relapse as topics of interest?
Yes. The announcement highlighted abstinence, withdrawal, and relapse as critical stages of interest, including neuroimmune dynamics during cessation of drug use, biological and behavioral processes during withdrawal, and mechanisms that may contribute to renewed drug seeking after a period of abstinence.
Was research on long-term neurological consequences of SUDs encouraged?
Yes. The FOA emphasized neurological consequences associated with SUDs, including brain changes that may persist and influence cognition, mood, stress responsivity, or vulnerability to future substance use.
How did the FOA frame neuroimmune responses in relation to addiction?
The broader goal was to advance an understudied area by determining whether neuroimmune responses function mainly as risk factors that worsen vulnerability and outcomes, as protective responses that buffer the brain and behavior, or as context-dependent mechanisms that can do either depending on factors like timing, substance type, dose, stress exposure, genetics, developmental stage, or comorbid conditions.
What practical outcomes was this research expected to support?
In practical terms, this framing supported research that could help identify new biomarkers of risk and progression, uncover novel therapeutic targets, and refine prevention or intervention strategies by accounting for immune-brain interactions.
What was the award ceiling for this opportunity?
The listed award ceiling for this opportunity was $200,000.
Was there a cost sharing or matching requirement?
No. There was no cost sharing or matching requirement stated for this program.
What CFDA number was associated with this program?
The program was associated with CFDA number 93.279, which corresponds to Drug Abuse and Addiction Research Programs.
Who was eligible to apply?
Eligibility was broad and included public and private institutions of higher education; nonprofits (with and without 501(c)(3) status); small businesses; for-profit organizations (including those other than small businesses); and multiple levels of government, including state, county, city or township governments, special district governments, and independent school districts.
Were tribal entities and specific mission-driven institutions eligible?
Yes. The FOA explicitly welcomed applications from tribal governments and tribal organizations, as well as institutions including HBCUs, Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian-serving institutions, and AANAPISIs.
Were faith-based and community-based organizations eligible?
Yes. Faith-based and community-based organizations were included among eligible applicants.
Could federal agencies apply?
Yes. Eligible federal agencies were included among the eligible applicant types.
Were foreign (non-U.S.) organizations eligible to apply?
Yes. Non-U.S. entities (foreign organizations and foreign institutions) were eligible to apply. In addition, non-U.S. components of U.S. organizations were eligible, and foreign components were allowed under NIH policy when scientifically justified.
When was this funding opportunity posted, and is it still active?
The opportunity was posted on February 4, 2014. The final listed closing date was May 7, 2017, and the archive date was June 7, 2017, indicating the FOA is no longer active but remains accessible for reference.
Where can the full announcement be found?
The full announcement was available through the NIH Grants Guide at: http://grants.nih.gov/grants/guide/pa-files/PA-14-083.html
Who should be contacted for access or linking issues related to the FOA page?
The NIH Office of Extramural Research (OER) webmaster contact provided for access or linking issues was: FBOWebmaster@OD.NIH.GOV
Browse more opportunities from the same category: Education Health
Next opportunity: Great Lakes Restoration Initiative Grants to Support Great Lakes Tribal Aquatic Invasive Species
Previous opportunity: Neuroimmune Signaling in Substance Use Disorders (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 14 083
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 14 083) also looked into and applied for these:
| Funding Opportunity |
|---|
| Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy (R01) Apply for PAR 14 085 Funding Number: PAR 14 085 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy (U01) Apply for PAR 14 086 Funding Number: PAR 14 086 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy (P01) Apply for PAR 14 087 Funding Number: PAR 14 087 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01) Apply for RFA DA 15 005 Funding Number: RFA DA 15 005 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| HIV Infection of the Central Nervous System (R01) Apply for PA 14 094 Funding Number: PA 14 094 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Eradication of HIV 1 from Central Nervous System Reservoirs (R01) Apply for PA 14 095 Funding Number: PA 14 095 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics toward Commercialization Apply for RFA CA 14 002 Funding Number: RFA CA 14 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| NIDA Avant Garde Award Program for HIV/AIDS and Drug Use Research (DP1) Apply for RFA DA 15 004 Funding Number: RFA DA 15 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Development of Software and Analysis Methods for Biomedical Big Data in Targeted Areas of High Need (U01) Apply for RFA HG 14 020 Funding Number: RFA HG 14 020 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Early Phase Clinical Trials in Imaging and Image Guided Interventions (R21) Apply for PAR 14 013 Funding Number: PAR 14 013 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Family Centered Self Management of Chronic Conditions (R21) Apply for PA 14 113 Funding Number: PA 14 113 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Family Centered Self Management of Chronic Conditions (R01) Apply for PA 14 112 Funding Number: PA 14 112 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R21) Apply for PAR 14 105 Funding Number: PAR 14 105 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R03) Apply for PAR 14 104 Funding Number: PAR 14 104 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01) Apply for PAR 14 106 Funding Number: PAR 14 106 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Additional Research Training Slots for NIDA Supported NRSA Institutional Training (T32) Grants (Admin Supp) Apply for PAR 14 115 Funding Number: PAR 14 115 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Quantitative Imaging for Evaluation of Response to Cancer Therapies (U01) Apply for PAR 14 116 Funding Number: PAR 14 116 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Accelerating Improvements in the HIV Care Continuum (R01) Apply for PA 14 132 Funding Number: PA 14 132 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R34) Apply for PA 14 135 Funding Number: PA 14 135 Agency: National Institutes of Health Category: Education Health Funding Amount: $225,000 |
| Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R21) Apply for PA 14 136 Funding Number: PA 14 136 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 14 083", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.